MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
Revenue of MyMD Pharmaceuticals, Inc. (MYMD)
Revenue in 2023 (TTM): $
According to MyMD Pharmaceuticals, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of MyMD Pharmaceuticals, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $ | $-17,123,050 | $-3,999,950 | $-3,999,950 |
| 2022 | $ | $ | $85.43 K | $-15,197,336 | $-15,111,909 |
| 2021 | $ | $ | $-28,809,707 | $-29,889,045 | $-29,880,138 |
| 2020 | $ | $-29,452 | $-8,277,772 | $-9,487,824 | $-10,679,683 |
| 2019 | $1.58 M | $1.5 M | $-3,946,077 | $-3,381,295 | $-3,888,249 |
| 2018 | $1.67 M | $127.29 K | $-10,060,409 | $-10,849,034 | $-10,849,034 |
| 2017 | $3.93 M | $2.51 M | $-5,052,806 | $-5,805,326 | $-5,805,326 |
| 2016 | $2.96 M | $1.88 M | $ | $-3,303,538 | $-3,303,538 |
| 2015 | $2.12 M | $1.16 M | $-9,682,230 | $-9,581,257 | $-9,311,913 |
| 2014 | $4.43 M | $3.25 M | $-2,777,769 | $-3,127,167 | $-3,127,167 |
| 2013 | $3.58 M | $1.66 M | $ | $-1,526,773 | $-1,526,773 |
| 2012 | $1.52 M | $546.41 K | $-2,074,542 | $-2,612,424 | $-2,449,051 |
| 2011 | $1.79 M | $890.51 K | $-3,356,836 | $-3,882,168 | $-3,584,278 |
| 2010 | $3.05 M | $1.77 M | $-719,267 | $-1,203,296 | $-919,883 |
| 2009 | $1.84 M | $743.46 K | $-3,707,527 | $-4,628,017 | $-4,628,017 |
| 2008 | $6.08 M | $4.71 M | $592.56 K | $-1,235,095 | $-535,159 |
| 2007 | $5.52 M | $3.51 M | $-1,740,676 | $-2,365,071 | $-1,724,614 |
| 2006 | $1.02 M | $-1,443,026 | $-8,828,960 | $-10,083,509 | $-9,594,647 |
| 2005 | $4.61 M | $1.67 M | $-3,856,913 | $-4,507,186 | $-4,507,186 |